Please cite this article in press as: Dervaux B, et al. What is the budget impact of a new treatment or new health technology arriving on the market? Therapie (2017), http://dx.doi.org/10.1016/j.therap.2016.12.003 ARTICLE IN PRESS +Model THERAP-131; No. of Pages 11 Therapie (2017) xxx, xxx—xxx Available online at ScienceDirect www.sciencedirect.com GIENS WORKSHOPS 2016 /Medico-economy What is the budget impact of a new treatment or new health technology arriving on the market?  Benoit Dervaux a , Camille Le Fur b , Sophie Dubois c,* , Anne Josseran d , the participants of round table No. 3 of Giens XXXIII, Éric Baseilhac e , uc Baumstark f , Olivier Blin g , Xavier Bresse h , Frédérique Debroucker i , Olivier Delaitre j , Bruno Detournay k , Vincent Diebolt l , Isabelle Durand-Zaleski m , Anne-Franc ¸oise Gaudin n , aure Huot o , Grégoire Jeanblanc p , Robert Launois q , Karine Levesque r , aurie Levy-Bachelot s a EA2694, santé publique : épidémiologie et qualité des soins, CHU de Lille, université de Lille, 59000 Lille, France b GlaxoSmithKline, 78163 Marly le Roi, France c Takeda, immeuble Pacific, 11-13, cours Valmy, 92977 La Défense, France d Sanofi, 94250 Gentilly, France e LEEM, 75017 Paris, France f UMR 5824, groupe d’analyse et de théorie économique (GATE), université Lyon, 69363 Lyon, France g UMR 7289, pharmacologie clinique et pharmacovigilance, AP—HM, Aix-Marseille université, 13000 Marseille, France h Sanofi-Pasteur MSD, 69367 Lyon, France i Medtronic, 92513 Boulogne-Billancourt, France j Boehringer Ingelheim France, 75644 Paris, France k Cemka-Eval, 92340 Bourg-la-Reine, France l F-CRIN, 31059 Toulouse, France m Inserm, UMR 1123, ECEVE, AP—HP, 75004 Paris, France n Bristol-Myers-Squibb, 92500 Rueil-Malmaison, France o Hospices civils de Lyon, 69002 Lyon, France DOI of original article: http://dx.doi.org/10.1016/j.therap.2016.12.002.  Articles, analyses and proposals from Giens workshops are those of the authors and do not prejudice the proposition of their parent organization. ∗ Corresponding author. E-mail address: sophie.dubois@takeda.com (S. Dubois). http://dx.doi.org/10.1016/j.therap.2016.12.003 0040-5957/© 2017 Soci´ et´ e franc ¸aise de pharmacologie et de th´ erapeutique. Published by Elsevier Masson SAS. All rights reserved.